VISINE Drug Patent Profile
✉ Email this page to a colleague
When do Visine patents expire, and when can generic versions of Visine launch?
Visine is a drug marketed by Johnson And Johnson and is included in two NDAs.
The generic ingredient in VISINE is oxymetazoline hydrochloride. There are three drug master file entries for this compound. Four suppliers are listed for this compound. Additional details are available on the oxymetazoline hydrochloride profile page.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for VISINE?
- What are the global sales for VISINE?
- What is Average Wholesale Price for VISINE?
Summary for VISINE
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 2 |
| Finished Product Suppliers / Packagers: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 106 |
| Clinical Trials: | 1 |
| Patent Applications: | 1,303 |
| DailyMed Link: | VISINE at DailyMed |
Recent Clinical Trials for VISINE
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Massachusetts Eye and Ear Infirmary | Phase 2 |
US Patents and Regulatory Information for VISINE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Johnson And Johnson | VISINE | naphazoline hydrochloride; pheniramine maleate | SOLUTION/DROPS;OPHTHALMIC | 020485-001 | Jan 31, 1996 | OTC | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Johnson And Johnson | VISINE L.R. | oxymetazoline hydrochloride | SOLUTION/DROPS;OPHTHALMIC | 019407-001 | Mar 31, 1989 | OTC | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
